| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000042252 |
| Receipt No. | R000048245 |
| Scientific Title | Evaluating the impact of wearing TRI-KNIT shirt on atopic dermatitis: a pilot study |
| Date of disclosure of the study information | 2020/11/01 |
| Last modified on | 2022/10/30 (Ver. 2) |
| Basic information | ||
| Public title | Evaluating the impact of wearing TRI-KNIT shirt on atopic dermatitis: a pilot study | |
| Acronym | The impact of wearing TRI-KNIT shirt on atopic dermatitis: | |
| Scientific Title | Evaluating the impact of wearing TRI-KNIT shirt on atopic dermatitis: a pilot study | |
| Scientific Title:Acronym | Evaluating the impact of wearing TRI-KNIT shirt on atopic dermatitis: a pilot study | |
| Region |
|
|
| Condition | ||
| Condition | atopic dermatitis | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | This study aims to explore the effects of atopic dermatitis on the skin and dermatitis status of patients with atopic dermatitis during the wearing of TRI-KNIT shirts. The results of this exploratory study can be expected to bring important suggestions for lifestyle guidance aimed at long-term maintenance of atopic dermatitis remission. It is an exploratory study to confirm the changes in the results of various tests and subjective assessments before and after the period of wearing this shirt. |
| Basic objectives2 | Others |
| Basic objectives -Others | The impact on symptoms will be investigated. |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | visual analogue scale (VAS) for itch
EASI: The Eczema Area and Severity Index |
| Key secondary outcomes | Patient background: gender, age, medical history, and treatment
Laboratory tests: white blood cell count, serum TARC (which is covered by insurance as a measure of the severity of atopic dermatitis), and IgE level POEM (patient oriented eczema measure): a self-administered assessment of the severity of the disease, a seven-question questionnaire TSQM9 (treatment satisfaction questionnaire for medication-9): A questionnaire with nine questions to assess satisfaction with the TRI-KNIT. Assessment of skin flora: swab the middle of the upper dorsal area Skin pH: measured by placing the probe of the measuring instrument on the skin. Non-invasive. Exfoliated moisture content: measured by placing the probe of the instrument on the skin. Non-invasive. Skin Moisture Checker: A patch that can be evaluated by simply applying it to the skin to check skin moisture content, which is sold by Life Care Giken. It is non-invasive. It is applied to the middle of the upper back, which is usually covered by clothing, for 5 minutes before and after the examination to evaluate the skin moistness. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | TRI-KNIT shirts | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1 Age 20 years or older 2 Gender Any gender 3 For outpatients. 4 Patients who have received sufficient information and understanding of the study, and who have given their free written consent to participate in the study. 5 Patients who have not shown any improvement in their symptoms after the same treatment in the last two months (this is the definition of refractory for this study). | |||
| Key exclusion criteria | none | |||
| Target sample size | 5 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Nagasaki university | ||||||
| Division name | Dermatology | ||||||
| Zip code | 8528501 | ||||||
| Address | 1-7-1, Sakamoto, Nagasaki city | ||||||
| TEL | 095-819-7333 | ||||||
| h-morisaki@nagasaki-u.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Nagasaki university | ||||||
| Division name | Dermatology | ||||||
| Zip code | 8528501 | ||||||
| Address | 1-7-1, Sakamoto, Nagasaki city | ||||||
| TEL | 095-819-7333 | ||||||
| Homepage URL | |||||||
| h-morisaki@nagasaki-u.ac.jp | |||||||
| Sponsor | |
| Institute | Nagasaki univrsity |
| Institute | |
| Department | |
| Funding Source | |
| Organization | ITOCHU Textile Prominent(ASIA)Limited |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Clinical research cencer, Nagasaki univrtsity |
| Address | 1-7-1 Sakamoto |
| Tel | 095-819-7726 |
| rinshou7726@umin.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000048245 |